Accolade Inc
NASDAQ:ACCD
Accolade Inc
NASDAQ:ACCD
Price:
7.5 USD
-1.7%
Market Closed
Updated:
May 1, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
-6.1
Current
-10
Median
12.5
Industry
Higher
than median
Lower
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=-6.1
Enterprise Value
/
553.9m
EBITDA
-90.4m
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| US |
|
Accolade Inc
NASDAQ:ACCD
|
577.2m USD | -6.1 | |
| US |
|
Cigna Corp
NYSE:CI
|
104.4B USD | 10.4 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
96.9B EUR | 10.3 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
72.9B USD | 8 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.7B EUR | 10.6 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
16.9B USD | 11.9 | |
| DE |
F
|
Fresenius SE & Co KGaA
XETRA:FRE
|
15.8B EUR | 10.1 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
15.2B USD | 10.7 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.6B EUR | 6.9 | |
| US |
|
DaVita Inc
NYSE:DVA
|
12.3B USD | 8.6 | |
| US |
|
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | -23.3 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
-66.8
2-Years Forward
EV/EBITDA
38.1
3-Years Forward
EV/EBITDA
15.9
You don't have any saved screeners yet
